Research Analysts Set Expectations for POAI Q4 Earnings

Predictive Oncology Inc. (NASDAQ:POAI) – Equities researchers at HC Wainwright increased their Q4 2025 EPS estimates for Predictive Oncology in a report issued on Friday, November 15th. HC Wainwright analyst S. Ramakanth now forecasts that the medical instruments supplier will earn $0.06 per share for the quarter, up from their prior estimate of $0.05. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Predictive Oncology’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Predictive Oncology’s FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Price Performance

POAI stock opened at $0.68 on Monday. The company’s 50 day simple moving average is $0.75 and its 200-day simple moving average is $1.05. Predictive Oncology has a 52-week low of $0.55 and a 52-week high of $3.76. The firm has a market capitalization of $4.54 million, a P/E ratio of -0.22 and a beta of 1.14.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.